VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Update

VolitionRX Limited (NYSEAMERICAN:VNRX) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 254,125 shares, a decline of 34.7% from the May 31st total of 389,005 shares. Based on an average daily volume of 424,498 shares, the short-interest ratio is currently 0.6 days. Approximately 3.2% of the company’s shares are short sold.

VolitionRX Stock Performance

Shares of VolitionRX stock opened at $1.36 on Thursday. The firm has a fifty day moving average of $2.12 and a two-hundred day moving average of $3.75. The stock has a market capitalization of $11.74 million, a price-to-earnings ratio of -0.33 and a beta of 1.12. VolitionRX has a 52 week low of $1.17 and a 52 week high of $16.39.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27). The company had revenue of $0.99 million during the quarter, compared to analyst estimates of $1.52 million. As a group, research analysts forecast that VolitionRX will post -2.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on VNRX shares. Citigroup cut VolitionRX to a “hold” rating in a research note on Monday, April 20th. Maxim Group reaffirmed a “buy” rating and set a $4.00 price target on shares of VolitionRX in a research note on Thursday, June 18th. Benchmark reiterated a “hold” rating on shares of VolitionRX in a research report on Tuesday, June 2nd. D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. Finally, HC Wainwright reduced their target price on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, VolitionRX currently has an average rating of “Hold” and a consensus target price of $28.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC increased its stake in VolitionRX by 166.6% in the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 67,848 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of VolitionRX during the fourth quarter worth $34,000. Jane Street Group LLC bought a new position in shares of VolitionRX during the fourth quarter worth $28,000. Geode Capital Management LLC grew its holdings in shares of VolitionRX by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after buying an additional 85,816 shares during the period. Finally, Armistice Capital LLC grew its holdings in shares of VolitionRX by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after buying an additional 887,351 shares during the period. Institutional investors own 8.09% of the company’s stock.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.